Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Arauca Capital Jean Philippe Tissot | “Sofwave Medical is an aesthetic medical device company that develops non-invasive ultrasound systems for skin lifting and wrinkle reduction. The manager remains strongly bullish following a recent share price decline, emphasizing that the market has overreacted to hypothetical competitive threats from Asian low-cost radiofrequency devices while overlooking the company's robust underlying recurring revenue trajectory. Sofwave functions as a razor-and-blade utilization platform: after selling base hardware units, it generates high-margin recurring income from per-treatment consumable transducer usage fees. This business model exhibited superior unit economics in Q2 2026, with usage revenue surging 51% to reach 46% of total sales and expanding overall gross margins to 76.5%. With $38.8 million in cash, negligible debt, and positive net income, Sofwave possesses operating leverage that should translate future top-line gains directly into free cash flow. At approximately 10 times projected 2028 earnings, valuation is considered highly disconnected from 40%+ revenue growth. Catalysts include operating margin expansion in the second half of 2026, ongoing adoption across global clinics, and provider network expansion in South Korea. Key risks involve prospective market share erosion from cheaper Asian aesthetic system alternatives and clinic-level treatment price competition.” | BULL | Q2 2026 Sep 1, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
